Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression☆,☆☆
References (51)
- et al.
- et al.
CRC Crit. Oncol. Hematol.
(1989)Adv. Cancer Res.
(1989)- et al.
Trends Biochem. Sci.
(1988)- et al.
J. Biol. Chem.
(1980) - et al.
J. Biol. Chem.
(1987) - et al.
J. Biol. Chem.
(1989)
Cancer Lett.
J. Biol. Chem.
Exp. Cell Res.
J. Pathol. Bacteriol.
Ann. Surg.
Cancer Res.
Cancer Res.
Cancer Res.
J. Cell. Biochem.
Cancer Res.
Cancer Res.
J. Natl. Cancer Inst.
Cancer Res.
Cancer Res.
Cancer Res.
Cited by (60)
A spectroscopic analysis of the interaction between MEGA10 and Concanavalin A
2019, Journal of Molecular LiquidsCitation Excerpt :The functionalization of nanocarriers using targeting ligands such as monoclonal antibodies, peptides fragments, folate, surfactants and carbohydrates deserved special attention [4–6]. In recent years, there has been growing interest in the use of carbohydrates-sensibilized nanoparticles that can be used to specifically bind lectin, a protein overexpressed on the surface of numerous cancer cells [7–9]. On the other hand, lectin-mediated drug targeting also include nanoparticles decorated with lectin for specific binding to sugar on the wall of diseased cells.
Role of galectin-3 in the pathogenesis of bladder transitional cell carcinoma
2015, Human ImmunologyCitation Excerpt :Galectin-3 secreted by tumor cells may effectively or preferentially activate antigen-experienced or tumor-reactive T cells to deliver cytokines and prompt apoptosis at a high level of concentration, thus inducing immune tolerance at tumor sites. Similar to other members of galectin protein family, galectin-3 is highly expressed in numerous tumor cell types [26–28]. In addition to its regulatory role in T-cell activation and immune tolerance, galectin-3 may be associated with tumor development as well as the destructive phenotype of tumors [29,30].
Galectin expression in cancer diagnosis and prognosis: A systematic review
2015, Biochimica et Biophysica Acta - Reviews on CancerCitation Excerpt :For example, most studies in brain cancer describe a positive correlation between tumor grade and galectin-3 expression levels [75,119,120]. Also in colon cancer, galectin-3 expression often correlates with tumor stage in colon cancer [29,114,115,121–123] while galectin-1 appears to positively correlate with stage in e.g. gastric cancer [124–126], ovarian cancer [27,127] and chronic lymphocytic leukemia [128]. Finally, galectin-7 and galectin-9 are frequently negatively correlated with tumor stage, grade or nodal involvement.
Tumor-released galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack
2014, Journal of Biological ChemistryCitation Excerpt :The overall homology of human intergalectins is ∼20%, but their carbohydrate recognition domains are relatively conserved (2). Previous studies showed that Gal-3 is highly expressed in many types of cancer cells (3–5). Depending on cell type and proliferative status, Gal-3 can exist in the cytoplasm, within the nucleus, on the cell surface, and in the extracellular compartment (6–8).
Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven
2008, Cancer LettersCitation Excerpt :Gal-1 binds β-galactoside groups on various cell surface receptors, is highly upregulated in tumor-activated endothelial cells, and is crucial for activated endothelial cells to adhere to, and to migrate on, the extracellular matrix [9,13–15]. Differential stromal elevation of gal-1 over the tumor parenchyma has been reported in several cancers including cancer of the breast [16], colon [17], prostate [18,19] and ovaries [20]. On the molecular level, interaction between anginex and galectin-1 inhibits tumor-activated endothelial cell proliferation via anoikis [21] and attenuates tumor angiogenesis and tumor growth [22–24].
Galectins as molecular targets for therapeutic intervention
2018, International Journal of Molecular Sciences
- ☆
This article is dedicated to Professors Toshiaki Osawa and Nathan Sharon who were doctoral thesis advisors for Tatsuro Irimura and Reuben Lotan, respectively.
- ☆☆
This study was supported by grants from the National Foundation for Cancer Research, The Council for Tobacco Research-USA, Inc. (No. 2546), the National Cancer Institute (CA-39319 and CA-50231), and The Texas Advanced Technology Program (No. 1549).